S&P 500   4,966.57 (-0.89%)
DOW   37,949.61 (+0.46%)
QQQ   414.51 (-2.10%)
AAPL   164.97 (-1.24%)
MSFT   399.04 (-1.29%)
META   480.40 (-4.26%)
GOOGL   153.83 (-1.40%)
AMZN   174.24 (-2.78%)
TSLA   147.09 (-1.89%)
NVDA   771.78 (-8.85%)
AMD   146.38 (-5.61%)
NIO   3.81 (-4.75%)
BABA   69.03 (+0.22%)
T   16.47 (+0.86%)
F   12.10 (+0.33%)
MU   106.15 (-5.16%)
GE   148.25 (-3.07%)
CGC   7.98 (+1.92%)
DIS   112.15 (-0.25%)
AMC   3.19 (+9.25%)
PFE   25.95 (+2.21%)
PYPL   61.92 (-0.29%)
XOM   119.90 (+1.16%)
S&P 500   4,966.57 (-0.89%)
DOW   37,949.61 (+0.46%)
QQQ   414.51 (-2.10%)
AAPL   164.97 (-1.24%)
MSFT   399.04 (-1.29%)
META   480.40 (-4.26%)
GOOGL   153.83 (-1.40%)
AMZN   174.24 (-2.78%)
TSLA   147.09 (-1.89%)
NVDA   771.78 (-8.85%)
AMD   146.38 (-5.61%)
NIO   3.81 (-4.75%)
BABA   69.03 (+0.22%)
T   16.47 (+0.86%)
F   12.10 (+0.33%)
MU   106.15 (-5.16%)
GE   148.25 (-3.07%)
CGC   7.98 (+1.92%)
DIS   112.15 (-0.25%)
AMC   3.19 (+9.25%)
PFE   25.95 (+2.21%)
PYPL   61.92 (-0.29%)
XOM   119.90 (+1.16%)
S&P 500   4,966.57 (-0.89%)
DOW   37,949.61 (+0.46%)
QQQ   414.51 (-2.10%)
AAPL   164.97 (-1.24%)
MSFT   399.04 (-1.29%)
META   480.40 (-4.26%)
GOOGL   153.83 (-1.40%)
AMZN   174.24 (-2.78%)
TSLA   147.09 (-1.89%)
NVDA   771.78 (-8.85%)
AMD   146.38 (-5.61%)
NIO   3.81 (-4.75%)
BABA   69.03 (+0.22%)
T   16.47 (+0.86%)
F   12.10 (+0.33%)
MU   106.15 (-5.16%)
GE   148.25 (-3.07%)
CGC   7.98 (+1.92%)
DIS   112.15 (-0.25%)
AMC   3.19 (+9.25%)
PFE   25.95 (+2.21%)
PYPL   61.92 (-0.29%)
XOM   119.90 (+1.16%)
S&P 500   4,966.57 (-0.89%)
DOW   37,949.61 (+0.46%)
QQQ   414.51 (-2.10%)
AAPL   164.97 (-1.24%)
MSFT   399.04 (-1.29%)
META   480.40 (-4.26%)
GOOGL   153.83 (-1.40%)
AMZN   174.24 (-2.78%)
TSLA   147.09 (-1.89%)
NVDA   771.78 (-8.85%)
AMD   146.38 (-5.61%)
NIO   3.81 (-4.75%)
BABA   69.03 (+0.22%)
T   16.47 (+0.86%)
F   12.10 (+0.33%)
MU   106.15 (-5.16%)
GE   148.25 (-3.07%)
CGC   7.98 (+1.92%)
DIS   112.15 (-0.25%)
AMC   3.19 (+9.25%)
PFE   25.95 (+2.21%)
PYPL   61.92 (-0.29%)
XOM   119.90 (+1.16%)
Free Trial
LON:ONC

Oncimmune (ONC) Share Price, News & Analysis

→ Here’s how to start a “Weekend Side Hustle” from your sofa (From DTI) (Ad)
Free ONC Stock Alerts
GBX 28
-1.10 (-3.78%)
(As of 01:43 PM ET)
Compare
Today's Range
27.50
▼
29
50-Day Range
16.80
▼
30.42
52-Week Range
13
▼
45
Volume
62,630 shs
Average Volume
76,900 shs
Market Capitalization
£20.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsHeadlinesInsider Trades
ONC stock logo

About Oncimmune Stock (LON:ONC)

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.

ONC Stock Price History

ONC Stock News Headlines

March 19, 2024 | wsj.com
Oncimmune Holdings PLC
March 2, 2024 | finance.yahoo.com
Oncimmune Holdings Full Year 2023 Earnings: UK£0.085 loss per share (vs UK£0.13 loss in FY 2022)
April 19, 2024 | WealthPress (Ad)
Chances are you know the firms on this list
These are the entities that can buy MILLIONS of shares in a single day… I’m talking about huge orders that literally move the share price 1%, 2%, even 5% or more in the process. Why am I showing you that list? Well, because if you have a way to successfully detect which stocks these elite traders are likely buying in real time… All you have to do is ride the coattails of their massive orders and you can target endless trading opportunities without leaving your money exposed to the markets for too long. And in case you didn’t already know…
February 15, 2024 | reuters.com
Cancer test firm Freenome raises $254 mln in fresh funding
February 14, 2024 | msn.com
Activist investor Kelso gains board seats at The Works as it tries to enhance shareholder value
December 2, 2023 | proactiveinvestors.com.au
Oncimmune seeing commercial traction as it inks new deals with big pharma companies
September 26, 2023 | yahoo.com
The Unique Use of Liquid Biopsy
August 1, 2023 | marketwatch.com
Oncimmune's Acting CEO Ron Kirschner Steps Down, Takes COO Role; Gouldstone Starts as CEO
April 19, 2024 | WealthPress (Ad)
Chances are you know the firms on this list
These are the entities that can buy MILLIONS of shares in a single day… I’m talking about huge orders that literally move the share price 1%, 2%, even 5% or more in the process. Why am I showing you that list? Well, because if you have a way to successfully detect which stocks these elite traders are likely buying in real time… All you have to do is ride the coattails of their massive orders and you can target endless trading opportunities without leaving your money exposed to the markets for too long. And in case you didn’t already know…
July 14, 2023 | marketwatch.com
Oncimmune Shares Fall As Company Lowers FY 2022 Revenue Result
July 12, 2023 | lse.co.uk
Oncimmune names chief executive successor, while finance chief leaves
July 12, 2023 | marketwatch.com
Oncimmune Holdings Appoints Martin Gouldstone CEO; CFO Matthew Hall to Step Down
June 23, 2023 | lse.co.uk
Oncimmune Holdings shakes up leadership and unveils new growth plan
June 23, 2023 | marketwatch.com
Oncimmune CEO Adam Hill to Step Down; Sees Tough End to FY 2023
May 31, 2023 | lse.co.uk
Oncimmune shares plummet as interim revenue falls by fifth
May 31, 2023 | marketwatch.com
Oncimmune Shares Fall on 1H Pretax Loss
May 22, 2023 | lse.co.uk
Oncimmune sells two subsidiaries to Freenome for GBP13 million
May 22, 2023 | markets.businessinsider.com
FREENOME ACQUIRES GLOBAL IMMUNODIAGNOSTICS DEVELOPER ONCIMMUNE LTD
May 22, 2023 | marketwatch.com
Oncimmune Eases Going-Concern Risk With Sale of Two Subsidiaries for GBP13 Mln
April 28, 2023 | marketwatch.com
The Comprehensive Guide to the Cancer Biopsy Market: Trends and Revenue Forecast with predicted CAGR of 4.2% from 2023-2030
April 22, 2023 | marketwatch.com
Cancer Biopsy Market Outlook by 2031
April 12, 2023 | finance.yahoo.com
Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
February 28, 2023 | proactiveinvestors.com
Oncimmune delivering top-line growth
February 27, 2023 | marketwatch.com
Oncimmune Shares Fall After Going Concern Warning, Pretax Loss
February 20, 2023 | lse.co.uk
CORRECT: Oncimmune works with Siemens Healthineers on cancer therapy
January 25, 2023 | theguardian.com
Richard Sharp: BBC chair was shareholder in firm awarded £600k while he was a No 10 adviser
January 2, 2023 | finance.yahoo.com
Investors in Oncimmune Holdings (LON:ONC) have unfortunately lost 67% over the last year
See More Headlines
Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncimmune and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/13/2018
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
LON:ONC
CUSIP
N/A
CIK
N/A
Web
oncimmune.com
Phone
+44-115-8231869
Fax
N/A
Employees
52
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
GBX (0.08)
Trailing P/E Ratio
N/A
Forward P/E Ratio
32.51
P/E Growth
N/A
Net Income
£-6,150,000.00
Net Margins
356.25%
Pretax Margin
N/A
Return on Equity
-760.96%
Return on Assets
-26.38%

Debt

Debt-to-Equity Ratio
806.85
Current Ratio
3.91
Quick Ratio
0.63

Sales & Book Value

Annual Sales
£1.15 million
Price / Sales
18.05
Cash Flow
GBX 2.34 per share
Price / Cash Flow
11.96
Book Value
GBX 1 per share
Price / Book
28.00

Miscellaneous

Outstanding Shares
74,140,000
Free Float
N/A
Market Cap
£20.76 million
Optionable
Not Optionable
Beta
1.12
Beginner's Guide to Pot Stock Investing Cover
Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Martin John Gouldstone (Age 58)
    CEO & Director
  • Mr. Martin Hudson
    Finance Director
  • Mr. Ron Kirschner (Age 45)
    COO, General Counsel & Company Secretary
  • Prof. Tariq Sethi B.Sc.
    FRCP, M.A., M.D., Ph.D., Chief Scientific Officer
  • Ms. Cléa Rosenfeld
    Head of Investor Relations
  • Mr. Maarten Brusse
    Chief Commercial Officer of Asia

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

ONC Stock Analysis - Frequently Asked Questions

How have ONC shares performed in 2024?

Oncimmune's stock was trading at GBX 25.20 at the start of the year. Since then, ONC stock has increased by 11.1% and is now trading at GBX 28.
View the best growth stocks for 2024 here.

How were Oncimmune's earnings last quarter?

Oncimmune Holdings plc (LON:ONC) released its earnings results on Tuesday, February, 13th. The company reported ($5.70) EPS for the quarter. The firm had revenue of $0.08 million for the quarter. Oncimmune had a negative trailing twelve-month return on equity of 760.96% and a net margin of 356.25%.

What other stocks do shareholders of Oncimmune own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncimmune investors own include Actinium Pharmaceuticals (ATNM), Digi International (DGII), SeaChange International (SEAC), SMTC (SMTX), Axsome Therapeutics (AXSM), Chimerix (CMRX) and Constellation Pharmaceuticals (CNST).

How do I buy shares of Oncimmune?

Shares of ONC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:ONC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
Your Money is Not Safe
American Alternative
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media
My biggest AI fear
Paradigm Press